News FAMHP

There are 64 result(s) found based on your search criteria

1-10 from 64 result(s)

Flash VIG-news: Gabapentin (Neurontin and generics) : risks of misuse, abuse, and dependence

The Summary of Product Characteristics (SPC) and package leaflet for gabapentin-containing medicines (Neurontin and generics in Belgium) have been updated following analyses of the risks of misuse, abuse and dependence.

Annual report on the donation of human body material: increase in the declarations of explicit content and reduction in opposition

In Belgium, each individual, after their death, is presumed to be a potential donor. Since 2020, as well as organ donation, any Belgian citizen has had the option to express their will, explicit consent or opposition to the post-mortem donation of human body material like skin, cartilage, tendons or heart values for transplantation, the manufacture of medicines (advanced therapies) and for scientific research.

Customs and the FAMHP seize 1.5 tonnes of illegal medicines

On 14 July 2023, customs and the FAMHP seized 1.5 tonnes of illegal medicines at Brucargo. This is one of the largest seizures in the European Union in recent years.

Give your opinion on a genetically modified vaccine for the treatment of colorectal tumors

The FPS Public Health and the FAMHP invite you to participate in the public consultation on a clinical trial testing the genetically modified vaccine Nous-209 for the treatment of colorectal tumors. The public consultation runs from 15 October 2022 to 14 November 2022.

The online medicinal products database gets an update

The FAMHP online medicinal products database contains information on all medicinal products for human and veterinary use authorised in Belgium. Some new functions have been added in this new version. This makes it easier to search for new medicinal products or active ingredients.

Impact of war in Ukraine on clinical trials

The current war in Ukraine has had a huge impact on clinical trials in Ukraine, Russia and Belarus. Due to the war, a large number of patients in these countries participating in clinical trials are no longer able to participate. There are also problems with the supply of medicinal products and other supplies for conducting clinical trials. The relevant authorities in countries within the European Union are making every effort to ensure the continuity of treatment for patients in ongoing clinical trials by providing the option to continue their treatment at trial sites abroad.

Iodine tablets : recommendations for citizens and pharmacists

Over the past few weeks, more than three hundred thousand citizens have obtained iodine tablets from their pharmacies as a result of the conflict in Ukraine. The FAMHP has listed a few recommendations.

The FAMHP encourages non-profit organisations and academia to apply for the pilot project for the repurposing of authorised medicines

The FAMHP takes part in the European pilot project for the repurposing of medicines to support non-profit organisations and academia. The project was launched by the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA).

Modification of the veterinary prescriptions and the administration and supply document

On 28 January 2022, the European Regulation on medicinal products for veterinary use has entered into force. Among other things, this implies that veterinarians have the obligation to use a new model format for veterinary prescriptions. These changes will take place in several phases.

New European rules on medicinal products for veterinary use as of 28 January 2022

As of 28 January 2022, Regulation 2019/6 became effective. From that moment onwards, European Member States must comply with all rules from this regulation.

1-10 from 64 result(s)